• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Tapping Compliance Data to Drive Success

Pharmaceutical ExecutivePharmaceutical Executive-08-01-2020
Volume 40
Issue 8

How pharma leaders can convert data collected for compliance purposes from a cost center into a critical success factor.

Xavier Duburcq

In the pharmaceutical sector, manufacturers have become accustomed to the significant and increasing “burden” of regulatory compliance demanding that they update their processes, systems, and skills to accommodate the latest reporting requirements. Of course, life sciences regulators exist to hold companies to account and keep customers safe, by enforcing certain standards and ensuring that manufacturers adhere to them over time (and can demonstrate, on demand, that they have done so).

But maintaining compliance can be relentless. Each time companies think they are on top of everything, specifications are updated or a new wave of change comes along. It can be demoralizing, and draining—from a time and resource perspective. A better way to drive value from an investment in compliance is to look for a wider range of wins. Traditionally, companies would have approached regulatory requirements as a necessary evil, something to satisfy the authorities and minimize business risk. Beyond this, organizations have not typically looked for strategic benefits.

A fresh approach to compliance

In today’s digital new world, there is a chance to treat compliance very differently. That’s as companies move away from processes built around manually filling in paper or PDF documents for each unique regulatory reporting requirement, toward building rich, dynamic databases whose contents can be repurposed many times over. A definitive central resource where all of the required information (and more besides) can be collated, checked, refined, and updated—so that anything else that happens thereafter with that information is, by default, correct and compliant.

The pharmaceutical sector has tended to be slow to adapt to the benefits of this approach—because of the legacy data, systems, and processes companies have had to unravel first. But unless they strive to do things fundamentally differently, they will be increasingly at a disadvantage.

Basing compliance activity on structured, ready-to-go data, in a consistent format, means the latest, correct information can be called up and prepared at speed using the latest digital tools to ensure efficient data exchanges with authorities, with full details and a clear line of sight across every product’s lifecycle—for reliability, traceability, and protected data access.

By harnessing these characteristics, pharma companies can start to think beyond the immediate goal of compliance for its own sake, and toward the wider benefits that come with being able to quickly access great detail about products, including their application, use, and efficacy in the real world.

Spotlight on non-compliance

Traditionally, audits, inspections, complaints handling, and pharmacovigilance have put the spotlight on non-compliance. It is why, in the US, we see lawyers and other professionals with roles dedicated to damage limitation and crisis management.

But what if positive action and preemptive compliance were made business differentiators? If they became a signal to the market, and to customers/patients, that a company has an enriched sense of public duty, of “wanting to do the right thing?” Amid the continued COVID-19 disruption, and the Black Lives Matter movement, there is an expectation that businesses review their culture, policies, and practices. Markets and customers have heightened sensitivity to whether companies are “walking the talk,” or whether everything they do is secondary to making a profit.

In life sciences chemistry, manufacuturing, and controls (CMC) and, more recently, safety disciplines, new concepts have been developed by adopting a proactive rather than a defensive approach to compliance. The quality by design initiative in CMC makes it possible to incorporate potential non-compliance risk in the development phase of the manufacturing process, for instance. The idea is to establish methods to increase robustness, minimizing post-market manufacturing inspection impacts. And, by extension, improve the patient experience by bringing better products to market, faster.

The premise of proactive safety planning is similar—eliminating more risk at the outset, simultaneously hitting two targets: a higher/faster market success rate; and becoming a more trusted brand/supplier. Here, risk management plans involve anticipating and paying close attention to an initial holistic review of all aspects (both positive and negative) of a product from its earliest development stages, allowing companies to anticipate and mitigate the safety profile of each drug.

In a world where more and more detail is captured about products, and shared with agencies right across their lifecycle—in some cases even made accessible to the public through digital channels—anticipating non-compliance becomes strategically important for a whole range of reasons. Companies don’t just want to avoid fines; they want to improve their safety records and show the public where their priorities really lie.

Companies can still look for cost efficiencies in all of this. Rather than lament next waves of regulatory demands, smart companies will look out for them—and be ready.

Maintaining ‘compliance intelligence’

The above requires maintaining active “compliance intelligence”—proactively identifying and anticipating trends in emerging rules, laws, or good practices. Regulation rarely comes out of nowhere. First, positioning papers are composed, shared, and developed. Then, guidelines and staged implementations follow, with time allowed for transition. Where once the tendency might have been to “wait and see,” in case of delays or changes to requirements, companies are realizing increasingly that deferring action can put them on the back foot and render them less able to capitalize on adjacent opportunities for the business—and for customers/patients.

With new waves of regulatory advancement never far away, there will never be a better time to transform compliance measures. We generally advise the relevant team within the company—or a suitable partner—to conduct a risk assessment within the context of the organization’s current business model, highlighting points to anticipate as new requirements appear on the horizon.

Companies might also consider spinning off compliance activity. This could involve appointing a dedicated team (usually associated with a risk management department)—or even relying on a service partner to outsource it. Once official requirements are published, the next task is to perform a gap analysis identifying all the potential implications. This might range from a simple but time-consuming review of a number of interrelated documents and data that will be involved, to potential additional technical and scientific work (e.g., to replace a banned ingredient or questionable material by another). Then companies must gain approval from the authorities for any changes made.

Proactive, not reactive

Where a company has adopted a proactive approach to compliance, or, better still, harnessed compliance as a lever to optimize the way it develops and manages drugs, then the smart thing to do is capture the lessons learned, perform a risk assessment, and engage in process changes through a controlled transformation process.

Reacting to each new compliance requirement as if it were an unwelcome surprise is no longer sustainable. Instead, businesses that are proactive in planning to address emerging compliance demands will benefit from compliance as an ongoing contributor to business success.

Xavier Duburcq, CEO, ProductLife Group

Related Videos
Related Content